Researchers recommend specific diabetes medications to protect bone health. Type 2 diabetes (T2D) and osteoporosis often coexist in patients, but managing both conditions can be a challenge. A comprehensive review highlights the most effective treatment options for treating these conditions together. Previous research has focused on the management of T2D and osteoporosis as separate diseases. However, several studies have shown that fracture risk is increasing in people with T2D. T2D directly affects bone metabolism and strength. Certain diabetes medications affect bone metabolism, and an association exists between diabetic complications and the risk for falls and subsequent fractures. They found that Metformin, sulfonylureas, DPP-4 inhibitors and GLP1 receptor agonists—medications for T2D—should be the preferred treatment for T2D in patients who also have osteoporosis. These medications were preferred because they can help protect bone health. Studies show that Metformin has beneficial effects on bone formation and bone mineral density. Positive or neutral effects have been seen in bone metabolism with the use of DPP-4 inhibitors and GLP1 receptor agonists. On the other hand, thiazolidinediones (TZDs) and canagliflozin should be avoided while other SGLT2 inhibitors are less well-validated options. Insulin should be used with caution and with careful measures to avoid hypoglycemia. To determine the most effective treatment options, the researchers systematically reviewed past human studies and guidelines to develop recommendations for the most appropriate joint treatment approaches for diabetes and osteoporosis. — “Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management,” published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2017-00042.